300119 瑞普生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)3.55210.3918.40112.72417.398
总资产报酬率 ROA (%)2.3087.1325.8788.60910.672
投入资产回报率 ROIC (%)2.7548.3166.80010.13713.067

边际利润分析
销售毛利率 (%)48.51949.68748.44151.80454.040
营业利润率 (%)17.20425.13319.99024.87925.651
息税前利润/营业总收入 (%)18.07626.04020.68625.23826.818
净利润/营业总收入 (%)15.26922.72217.93321.60221.970

收益指标分析
经营活动净收益/利润总额(%)89.62566.11085.14072.81079.075
价值变动净收益/利润总额(%)8.78113.48413.39627.11523.146
营业外收支净额/利润总额(%)-0.4090.256-0.683-2.372-0.431

偿债能力分析
流动比率 (X)1.8052.4262.3622.7241.829
速动比率 (X)1.5742.1372.0812.4041.414
资产负债率 (%)32.14227.15426.28724.0240.298
带息债务/全部投入资本 (%)21.30517.97417.48515.51917.139
股东权益/带息债务 (%)354.700442.670460.543524.461449.265
股东权益/负债合计 (%)192.994251.042262.994294.971211.284
利息保障倍数 (X)19.19530.92024.85526.96820.992

营运能力分析
应收账款周转天数 (天)158.521134.895113.60091.10171.166
存货周转天数 (天)124.632120.421121.862134.805122.881